:quality(90))
Phase III GRADUATE studies did not meet their primary endpoints of slowing clinical decline in people with early Alzheimer’sThe level of beta-amyloid removal by gantenerumab was lower than expected...| www.roche.com
Alzheimer's Association national site – information on Alzheimer's disease and dementia symptoms, diagnosis, stages, treatment, care and support resources.| Alzheimer’s Association
The US Food and Drug Administration’s controversial recent approval of Alzheimer’s drug Aduhelm has been subject to vociferous criticism from many in the scientific community. Amidst concerns surrounding the drug’s efficacy and price, several expert advisors to the FDA have resigned in protest and…| New Atlas
Pharmaceutical companies Eisai and Biogen have announced the first results from a Phase 3 human trial testing a drug designed to treat symptoms of dementia associated with Alzheimer’s disease. The drug seems to be successful at slowing cognitive decline, making it the first drug to ever effectively…| New Atlas
A new Alzheimer’s disease treatment has been controversially approved for use in the United States despite an independent Food and Drug Administration (FDA) advisory panel reporting last year the drug’s Phase 3 trial results were inconclusive. The approval marks the first new treatment for…| New Atlas
Last year, the FDA gave accelerated approval of the antibody aducanumab (marketed as Aduhelm by Biogen) for the treatment of Alzheimer's disease. The approval was based solely on a presumed reduction in the amount of the protein "amyloid" in the brain as assessed by amyloid-PET scans and without evidence of significant clinical effect.| medicalxpress.com